• Alzamend Neuro received a Nasdaq notice that it is not in compliance with Listing Rule 5550(b)(1) after reporting stockholders’ equity of about 2.2 million.
• Nasdaq requires at least 2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market.
• The company has 45 calendar days, until May 4, 2026, to submit a plan to regain compliance.
• If Nasdaq accepts the plan, it may grant up to 180 calendar days from the notice date, until September 16, 2026, to evidence compliance.
• Failure to regain compliance could result in a delisting notice, with the option to appeal to a Nasdaq Hearings Panel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-003620), on March 20, 2026, and is solely responsible for the information contained therein.